stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) Return on equity
United Therapeutics Corporation's return on equity over the twelve months to 30 September 2026 was 19.1%, down 0.6 percentage points from fiscal 2025 (19.7%). Over the past ten years it has ranged from −3.75% (fiscal 2019) to 46.0% (fiscal 2015); the current reading is higher than 64% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 19.7% | 0.48 |
| FY2024 | 19.2% | 0.96 |
| FY2023 | 18.3% | 1.66 |
| FY2022 | 16.6% | 3.67 |
| FY2021 | 12.9% | (3.73) |
| FY2020 | 16.7% | 20.42 |
| FY2019 | −3.75% | (27.85) |
| FY2018 | 24.1% | 2.96 |
| FY2017 | 21.1% | (20.36) |
| FY2016 | 41.5% | (4.53) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. compare | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.4% |
| UTHR United Therapeutics Corporation | 19.1% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 6.65% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| TAK Takeda Pharmaceutical Co. compare | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on UTHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement